IPM Take
Alzheimer’s access is no longer only about whether a drug works. It is about whether a system can move quickly enough after deciding that a drug may be worth funding.
Canada’s final positive recommendation for Leqembi is a meaningful step for eligible people with early Alzheimer’s disease. But it is not public reimbursement, and it is not patient access. The file now moves into price negotiation and provincial or territorial decisions, while patients still need timely diagnosis, biomarker confirmation, specialist assessment and monitoring capacity.
A recommendation is not treatment. It is only the point where the next bottleneck becomes visible.
Executive Summary
Eisai and Biogen announced that Canada’s Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi, lecanemab, for eligible patients with mild cognitive impairment or mild dementia due to early Alzheimer’s disease.
The recommendation follows reconsideration and represents an important HTA and reimbursement milestone in Canada. The next steps include negotiation through the pan-Canadian Pharmaceutical Alliance and then individual reimbursement decisions by provinces and territories.
Leqembi is an anti-amyloid monoclonal antibody. Access depends not only on reimbursement, but also on early diagnosis, amyloid confirmation, MRI monitoring, clinician capacity and safety management, including amyloid-related imaging abnormalities.
This is not yet broad funded access. It is a positive recommendation that may allow the public reimbursement process to move forward.
Why it matters
- Patients / advocates: People with early Alzheimer’s disease face a narrow treatment window. Administrative delay can become clinical exclusion.
- Clinicians: Treatment pathways require diagnostic confirmation, eligibility assessment and monitoring infrastructure, not just a reimbursement listing.
- Payers: Canada now has to decide how to manage price, eligibility and system capacity without turning access into a postcode lottery.
- Public authorities: Provincial implementation will decide whether national recommendation translates into equitable access.
Alzheimer’s policy is entering the uncomfortable space between approval and availability. This is where patients often learn that a medicine can exist, be reviewed, be recommended and still remain out of reach.
Canada’s Leqembi recommendation matters because it moves an anti-amyloid therapy closer to public funding for a defined early Alzheimer’s population. For patients and families trying to act while cognitive decline is still mild, the difference between a recommendation and a listing is not technical. It is time.
But the access pathway remains crowded. Provinces and territories still have to make funding decisions after pricing negotiations. Clinics need the ability to identify eligible patients early, confirm amyloid pathology and monitor safety. MRI capacity, specialist availability and referral speed will shape whether the recommendation becomes practical care or a policy announcement that patients cannot use quickly enough.
The political danger is that the system treats reimbursement as the final access decision. It is not. For Alzheimer’s therapies, diagnosis and monitoring are part of the treatment infrastructure. If they are missing, slow or available only in better-resourced regions, the access gap simply moves from the drug budget into the care pathway.
For IPM, the Canadian story is clear: a positive recommendation is progress, but it is not the finish line. The real measure will be whether eligible patients can move from concern, to diagnosis, to confirmation, to treatment decision before the disease moves beyond the window the system claims to target.
